Antiva Biosciences Closes $15 Million Series C-1 FinancingHillhouse, an investor with deep experience in China, led the round. Funding will accelerate additional clinical trials SOUTH SAN FRANCISCO, Calif., July 10, 2018-- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, has raised $15 million in Series C-1 financing led by Hillhouse Capital Management. Sirona Capital, along with existing investors Canaan Partners, Sofinnova Ventures, Brace Pharma Capital, Osage University Partners and Lumira Capital also participated in the round.